In a very short time, the target discovery approach that is applied in the collaboration has been validated as the first novel target proteins have been confirmed in cellular models of AML. Furthermore, by eliminating target proteins with potential safety risks early on in the process, the collaboration can deliver drug discovery programs with improved safety profiles.
The feasibility for further development in
“These early successes give support for our approach and this is now established as a reliable tool for novel target generation. We expect to generate a multitude of novel target proteins in AML and the collaboration may also be expanded to other types of cancers. This provides us with target proteins that have first-in-class potential, as well as high value by evaluation of safety and efficacy at an early stage,” said
The collaboration is aiming at identifying novel target proteins for AML treatments and applies an innovative combination of bioinformatics, CRISPR screening and safety assessment.
About the collaboration with Associate Professor Julian Walfridsson
With the goal of finding new, innovative treatments for AML,
© Modular Finance, source